Hot Features
Überwachen Sie mehrere Echtzeitkurse von führenden Börsen wie NASDAQ, NYSE, AMEX, Bovespa und mehr.
THE PANCREATIC CANCER ACTION NETWORK SELECTS ONCOLYTICS BIOTECH® INC. TO RECEIVE $5 MILLION THERAPEUTIC ACCELERATOR AWARD TO DEVELOP LEADING-EDGE TREATMENTS PR Newswire BOSTON and SAN DIEGO and...
New Developments in Fight Against Blood Cancers, in Leadup to US$17.1 Billion Market by 2024 FN Media Group Presents USA News Group News Commentary PR Newswire VANCOUVER, BC, Jan. 10, 2022...
New Developments in Fight Against Blood Cancers, in Leadup to US$17.1 Billion Market by 2024 FN Media Group Presents USA News Group News Commentary PR Newswire VANCOUVER, BC, Jan. 10, 2022...
CALGARY, Alberta and SAN DIEGO, Dec. 12, 2018 (GLOBE NEWSWIRE) -- Oncolytics Biotech® Inc. (NASDAQ: ONCY) (TSX: ONC), currently developing pelareorep, an intravenously delivered...
- Increased PD-L1 expression correlates with clinical response when pelareorep is combined with a proteasome inhibitor - - Data continue to recommend pelareorep as a standardized backbone for...
CALGARY, Alberta and SAN DIEGO, Nov. 29, 2018 (GLOBE NEWSWIRE) -- Oncolytics Biotech® Inc. (NASDAQ: ONCY) (TSX: ONC), currently developing pelareorep, an intravenously delivered...
CALGARY, Alberta and SAN DIEGO, Nov. 26, 2018 (GLOBE NEWSWIRE) -- Oncolytics Biotech® Inc. (NASDAQ: ONCY) (TSX: ONC), currently developing pelareorep, an intravenously delivered...
CALGARY, Alberta and SAN DIEGO, Nov. 13, 2018 (GLOBE NEWSWIRE) -- Oncolytics Biotech® Inc. (NASDAQ: ONCY) (TSX: ONC), currently developing pelareorep, an intravenously delivered...
- Checkpoint combination studies support progression into registration pathway for metastatic breast cancer and potential expansion of indications - - Management to host webcast and conference...
- Oncolytic virus enhances immune checkpoint inhibitor response in prostate cancers - CALGARY, Alberta and SAN DIEGO, Nov. 09, 2018 (GLOBE NEWSWIRE) -- Oncolytics Biotech® Inc. (NASDAQ: ONCY...
| Zeitraum † | Änderung | Änderung % | Handelsbeginn | Hoch | Niedrig | Durchsch. Volumen | VWAP | |
|---|---|---|---|---|---|---|---|---|
| 1 | -0.02 | -1.48148148148 | 1.35 | 1.47 | 1.28 | 223463 | 1.39690522 | CS |
| 4 | 0.07 | 5.55555555556 | 1.26 | 1.47 | 1.02 | 203727 | 1.26327435 | CS |
| 12 | -0.71 | -34.8039215686 | 2.04 | 2.04 | 1.02 | 138960 | 1.44730478 | CS |
| 26 | -0.03 | -2.20588235294 | 1.36 | 2.08 | 1.02 | 97726 | 1.45494131 | CS |
| 52 | -0.45 | -25.2808988764 | 1.78 | 2.08 | 1.02 | 80161 | 1.46536457 | CS |
| 156 | -0.47 | -26.1111111111 | 1.8 | 4.49 | 1.02 | 82475 | 2.19726034 | CS |
| 260 | -3.91 | -74.6183206107 | 5.24 | 7.84 | 1.02 | 131284 | 3.05659613 | CS |
| Keine Diskussionen Gefunden. |
| Neuen Thread Erstellen |
Support: +44 (0) 203 8794 460 | support@advfn.de
Durch das Benutzen des ADVFN Angebotes akzeptieren Sie folgende Allgemeine Geschäftsbedingungen
Premium
